Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Sol Shenker"'
Autor:
Karrie Wong, Sharon Lin, Christopher Wrocklage, Katri Sofjan, Leila Williams, Mallory Brady, Nicholas Colletti, Noah Tubo, Hugh Gannon, Robert LaMothe, Tianlei Xu, Tracy VandenBerg, Sol Shenker, Caroline Dugopolski, Frank Stegmeier, Louise Cadzow, Michael Schlabach, Micah Benson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/490a3e91b10d4fd1b0d7fff1fe4208ff
Autor:
Jakub O. Westholm, Pedro Miura, Sara Olson, Sol Shenker, Brian Joseph, Piero Sanfilippo, Susan E. Celniker, Brenton R. Graveley, Eric C. Lai
Publikováno v:
Cell Reports, Vol 9, Iss 5, Pp 1966-1980 (2014)
Summary: Circularization was recently recognized to broadly expand transcriptome complexity. Here, we exploit massive Drosophila total RNA-sequencing data, >5 billion paired-end reads from >100 libraries covering diverse developmental stages, tissues
Externí odkaz:
https://doaj.org/article/fe79549a28ff41f09b8c144dc74c610f
Autor:
Peter Smibert, Pedro Miura, Jakub O. Westholm, Sol Shenker, Gemma May, Michael O. Duff, Dayu Zhang, Brian D. Eads, Joe Carlson, James B. Brown, Robert C. Eisman, Justen Andrews, Thomas Kaufman, Peter Cherbas, Susan E. Celniker, Brenton R. Graveley, Eric C. Lai
Publikováno v:
Cell Reports, Vol 1, Iss 3, Pp 277-289 (2012)
We analyzed the usage and consequences of alternative cleavage and polyadenylation (APA) in Drosophila melanogaster by using >1 billion reads of stranded mRNA-seq across a variety of dissected tissues. Beyond demonstrating that a majority of fly tran
Externí odkaz:
https://doaj.org/article/284d5c71c22741fdbc558274abeb334a
Publikováno v:
PLoS Computational Biology, Vol 11, Iss 9, p e1004441 (2015)
Mirtrons are microRNA (miRNA) substrates that utilize the splicing machinery to bypass the necessity of Drosha cleavage for their biogenesis. Expanding our recent efforts for mammalian mirtron annotation, we use meta-analysis of aggregate datasets to
Externí odkaz:
https://doaj.org/article/b152366d05a64426bcbb08c8baaae75d
Autor:
Peter Smibert, Pedro Miura, Jakub O. Westholm, Sol Shenker, Gemma May, Michael O. Duff, Dayu Zhang, Brian D. Eads, Joe Carlson, James B. Brown, Robert C. Eisman, Justen Andrews, Thomas Kaufman, Peter Cherbas, Susan E. Celniker, Brenton R. Graveley, Eric C. Lai
Publikováno v:
Cell Reports, Vol 3, Iss 3, p 969 (2013)
Externí odkaz:
https://doaj.org/article/c9c98bce815640bd830f0e5ca4bd156d
Autor:
Sharon Lin, Leila Williams, Mitali Ghose, Hugh Gannon, Conor Calnan, Angelina Pizzo, Pei-Lun Kao, Mallory Brady, Katri Sofjan, Anne Dodson, Sol Shenker, Michael Schlabach, Fiona Sharp, Frank Stegmeier, Micah Benson, Karrie Wong
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Erica Tobin, Pamela Sullivan, Morgan Murray, Hugh Gannon, Anne Dodson, Sol Shenker, Frank Stegmeier, Andrew Wylie, Louise Cadzow
Publikováno v:
Cancer Research. 83:1581-1581
Tumors harboring BRCA1/2 mutations and other homologous recombination deficiencies are sensitive to agents targeting pathways involved in DNA repair including poly (ADP-ribose) polymerase (PARP) inhibitors, which have been approved for the treatment
Autor:
Sumeet Nayak, Pamela Sullivan, Yuji Mishina, Anne Dodson, Pei-Lun Kao, Hugh Gannon, Chris Middleton, Sol Shenker, Morgan Murray, Michael Schlabach, Frank Stegmeier, Erica Tobin, Louise Cadzow, Andrew Wylie
Publikováno v:
Cancer Research. 83:2771-2771
Tumors with defects in DNA double strand break (DSB) repair pathways, including those with mutations in BRCA1/2, are often treated with either poly (ADP-ribose) polymerase-1 (PARP1) inhibitors or platinum-based chemotherapy. Despite their clinical be
Autor:
Louise Cadzow, Erica Tobin, Pamela Sullivan, Sol Shenker, Sumeet Nayak, Janid Ali, Hugh Gannon, Anne Dodson, Paula Grasberger, Alyssa Carlson, Michael McGuire, Jehrod Brenneman, Hanlan Liu, Andrew Olaharski, Kerstin Sinkevicius, Jeff Hixon, Elsa Krall, Mike Schlabach, Matt Goulet, Jeremy Wilt, Patricia Harris, Frank Stegmeier, Andrew Wylie
Publikováno v:
Cancer Research. 82:ND01-ND01
Tumors with BRCA1/2 mutations and other homologous repair deficiencies (HRD) are vulnerable to agents that target the remaining DNA repair pathways, including platinum-containing chemotherapy agents and molecules targeting poly (ADP-ribose) polymeras
Autor:
Katri Sofjan, Sharon Lin, Sol Shenker, Caroline Dugopolski, Leila Williams, Karrie Wong, Christopher Wrocklage, Mallory Brady, Hugh S. Gannon, Frank Stegmeier, Robert A. LaMothe, Tracy VandenBerg, Noah Tubo, Micah J. Benson, Tianlei Xu, Nicholas John Colletti, Michael R. Schlabach, Louise Cadzow
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundAdoptive cell therapy with ex vivo expanded tumor infiltrating lymphocytes (TIL) offers a potentially curative treatment for cancer. However, the immunosuppressive tumor microenvironment limits the effectiveness of TIL therapy. To address t